Orthobiologics Market Size and Share
Market Definition
Biologic and biochemical products with application across orthopedics.
April 2026
Mike Evers, Senior Market Analyst
Welcome to our orthobiologics market overview. This page supplements the orthobiologics chapter in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT®.
Orthobiologics generated more than $5.8 billion in worldwide sales during 2025, accounting for 9% of all orthopedic revenue. Spine and trauma are the segments most closely tied to orthobiologics, but we expect these products to play an increasingly important role across orthopedics as the science advances and cost-effective therapies become widely available.
Market Forecast
The orthobiologics market is stable with the potential for accelerated growth as new treatments are approved and adopted. However, new treatment options face a high bar for regulatory approval and must find ways to be economically viable.
Exhibit 1: Worldwide Orthobiologics Sales by Year ($million)
Get More Orthopedic Market Data. Download the Orthopedic Companies Sales Matrix for our most complete and granular numbers. It contains worldwide orthopedic sales for 80 public and private companies by segment from 2016 through 2025.
Here are some of the orthobiologic market dynamics we considered in our forecasts:
Growing Health Crisis. Joint osteoarthritis (OA) affects 32.5 million adults in the United States with an overall economic burden of $137 billion annually, according to estimates by the U.S. Centers for Disease Control and Prevention.
The economic burden has more than doubled over the last decade.
Additionally, research suggests that arthritis-related activity limitations contribute to the lower employment rates of working-age individuals with OA. The number of impacted adults in the United States could double by 2040. Orthobiologics that target OA pain will see sustained, robust demand and investments.
Promising Contenders Face Major Hurdles. Knee osteoarthritis (KOA) is a major societal health and economic burden requiring new treatment solutions.
While the outlook for this area is promising, the industry has seen multiple other products fail to achieve statistically significant results capable of supporting FDA approval through the PMA or BLA pathways, and those companies went bankrupt or restructured to prioritize other targets.
Likewise, multiple late-stage treatment options for degenerative disc disease are nearing regulatory approval, marking a potential turning point for the treatment that bridges the gap between management and fusion.
Combination Care. Surgeons we’ve spoken with have identified biologics as the future and next wave of innovation in spine surgery, saying the combination of implants and orthobiologics could reduce the need for revision surgery.
It is becoming increasingly clear that the intersection of technology, implants and biologics is where the greatest strides can be made in improving surgical outcomes.
More Market Overviews
Sales by Region
There are abundant opportunities in the U.S. and international markets for orthobiologics companies. Two of the fastest growing players in the space, Kuros Biosciences and BONESUPPORT, have strategically targeted the U.S. market and generated tremendous growth there. Kuros Biosciences’ U.S. growth was nearly 72% in 2025, while BONESUPPORT grew almost 36%.
Outside the United States, Bioventus grew its pain and joint business 17% and said international markets represent a great opportunity in 2026 and beyond. Anika Therapeutics’ CINGAL surpassed 1 million injections across more than 40 international markets as it gains clinical adoption.
Exhibit 2: Orthobiologics Sales by Region ($million)
| Region | 2025 | 2024 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $4,099.3 | $3,960.2 | $139.1 | 3.5% |
| OUS | $1,765.2 | $1,721.6 | $43.6 | 2.5% |
| EMEA | $967.6 | $943.2 | $24.5 | 2.6% |
| APAC | $639.2 | $625.0 | $14.2 | 2.3% |
| ROW | $158.3 | $153.4 | $4.9 | 3.2% |
| Total | $5,864.5 | $5,681.8 | $182.7 | 3.2% |
Exhibit 3: Orthobiologics Market Share by Region ($million)
Top Companies
Orthobiologics is a large and diverse market leading to a somewhat fragmented landscape. A relatively smooth gradient of revenue spans across the tiers, meaning no company has a dominant market share.
By our estimates, more than 20 companies have at least $50 million in annual revenue, and no company has more than 9.6% market share.
As we’ll show below, orthobiologics is a major M&A target, but the transactions tend to be for smaller companies or select assets. Therefore, we expect the competitive landscape to remain fragmented going forward.
Exhibit 4: Top 10 Orthobiologics Players and All Others ($million)
| Company | 2025 | 2024 | $ Chg | % Chg |
|---|---|---|---|---|
| Medtronic | $563.1 | $546.5 | $16.6 | 3% |
| MTF Biologics | $525.0 | $512.0 | $13.0 | 2.5% |
| Bioventus | $408.3 | $387.2 | $21.0 | 5.4% |
| LifeNet Health | $351.0 | $339.0 | $12.0 | 3.5% |
| J&J MedTech | $343.7 | $350.1 | ($6.4) | (1.8%) |
| Stryker | $328.2 | $324.1 | $4.1 | 1.3% |
| Sanofi | $258.8 | $271.0 | ($12.2) | (4.5%) |
| Heraeus | $252.9 | $239.0 | $13.9 | 5.8% |
| AlloSource | $185.0 | $179.4 | $5.6 | 3.1% |
| Arthrex | $158.9 | $153.1 | $5.7 | 3.8% |
| All Others | $2,489.7 | $2,380.3 | $109.3 | 4.4% |
| Total | $5,864.5 | $5,681.8 | $182.7 | 3.2% |
Exhibit 5: Orthobiologics Market Share by Company ($million)
MTF Biologics expanded its collaboration with Kolosis BIO, adding DBX Mix and DBX Putty, and in 2026, Summit Matrix to the list of products Kolosis distributes for the company.
Bioventus signed an agreement with APEX Biologix to be the exclusive distributor of their XCELL PRP system in the United States for orthopedics and sports medicine, with revenue impact expected in 2026.
Further down the segment’s revenue scale, Globus Medical worked to realign its orthobiologics strategy due to changes in the reimbursement landscape.
Likewise, Orthofix contended with softness in biologics sales while restructuring its commercial channel within the segment.
Zimmer Biomet said it failed to budget adequately for its hyaluronic acid (HA) injection business and had to focus elsewhere amid a bevy of M&A integrations.
Seikgaku saw a slight decline in the Japanese HA injection market and a shift to single injection treatments in the United States
Kuros Biosciences continued opening doors in 2025, hitting the milestone of 100,000 surgeries with MagnetOs, a biologic bone graft technology, and continuing its run as one of the best growth stories in orthopedics.
BONESUPPORT drove excellent growth in the U.S. market during 2025 and announced a change in the regulatory process for the company’s market application to FDA for CERAMENT V for the indication of bone infection. The company transferred the application to the De Novo process, allowing for the opportunity to establish a new product category.
Important Developments in the Orthobiologics Market
Strategic Priority for M&A. Biologics made up 11% of orthopedic M&A from 2016 through 2020. Since 2021, however, the segment accounts for 20% of all deals. That 9% jump makes biologics the fastest-growing segment for M&A in recent years.
M&A activity slowed in 2025, biologics or otherwise, but Heraeus acquired bone void filler and bone substitute products, while Keensight Capital and Demetra were also active. Due to the sheer number of companies with small orthobiologic portfolios, we expect further consolidation to take place in the market.
Growth Engine for Differentiated Players. The United States is the largest orthobiologics market and is highly competitive. Companies like Kuros Biosciences and BONESUPPORT have driven industry-leading growth on the strength of their differentiated offerings.
Kuros Biosciences’ U.S. sales exceeded $140 million in 2025, a massive 71.7% jump from its 2024 total. The company recently expanded its indications to foot and ankle as well as core trauma, extending its runway for strong growth.
BONESUPPORT grew almost 36% in the U.S. market, driven largely by the strength of CERAMENT DE.
Anika Therapeutics continues to navigate the FDA regulatory process for Hyalofast and Cingal, both of which could add significant fuel to the company’s U.S. sales.
Evidence Gap Addressed. Orthobiologics products lack long-term clinical data, as well as inconsistent formulation and dosing standards. In response, surgeon associations are establishing registries and expanding educational initiatives to better differentiate products and guide clinical use.
Across the market, companies will need to invest in robust clinical and economic evidence to demonstrate product efficacy and value.
Further Reading
Thanks for visiting! Need more insight into the orthobiologics market? Questions and comments are always welcome. You can reach me by email. Until then, check out this selection of orthobiologics-related posts from recent months.
January 30, 2026
,
James Petricek and Scott Bruder
December 4, 2025
,
James Petricek and Scott Bruder
August 1, 2025
,
James Petricek and Scott Bruder
Our overview of the orthobiologics market includes up-to-date information on forecasted growth, the top companies and industry-driving trends.
Market Definition
Biologic and biochemical products with application across orthopedics.
April 2026
Mike Evers, Senior Market Analyst
Welcome to our orthobiologics market overview. This page supplements the orthobiologics chapter in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT®.
Orthobiologics generated more than $5.8 billion in worldwide sales during 2025, accounting for 9% of all orthopedic revenue. Spine and trauma are the segments most closely tied to orthobiologics, but we expect these products to play an increasingly important role across orthopedics as the science advances and cost-effective therapies become widely available.
Market Forecast
The orthobiologics market is stable with the potential for accelerated growth as new treatments are approved and adopted. However, new treatment options face a high bar for regulatory approval and must find ways to be economically viable.
Exhibit 1: Worldwide Orthobiologics Sales by Year ($million)
Get More Orthopedic Market Data. Download the Orthopedic Companies Sales Matrix for our most complete and granular numbers. It contains worldwide orthopedic sales for 80 public and private companies by segment from 2016 through 2025.
Here are some of the orthobiologic market dynamics we considered in our forecasts:
Growing Health Crisis. Joint osteoarthritis (OA) affects 32.5 million adults in the United States with an overall economic burden of $137 billion annually, according to estimates by the U.S. Centers for Disease Control and Prevention.
The economic burden has more than doubled over the last decade.
Additionally, research suggests that arthritis-related activity limitations contribute to the lower employment rates of working-age individuals with OA. The number of impacted adults in the United States could double by 2040. Orthobiologics that target OA pain will see sustained, robust demand and investments.
Promising Contenders Face Major Hurdles. Knee osteoarthritis (KOA) is a major societal health and economic burden requiring new treatment solutions.
While the outlook for this area is promising, the industry has seen multiple other products fail to achieve statistically significant results capable of supporting FDA approval through the PMA or BLA pathways, and those companies went bankrupt or restructured to prioritize other targets.
Likewise, multiple late-stage treatment options for degenerative disc disease are nearing regulatory approval, marking a potential turning point for the treatment that bridges the gap between management and fusion.
Combination Care. Surgeons we’ve spoken with have identified biologics as the future and next wave of innovation in spine surgery, saying the combination of implants and orthobiologics could reduce the need for revision surgery.
It is becoming increasingly clear that the intersection of technology, implants and biologics is where the greatest strides can be made in improving surgical outcomes.
More Market Overviews
Sales by Region
There are abundant opportunities in the U.S. and international markets for orthobiologics companies. Two of the fastest growing players in the space, Kuros Biosciences and BONESUPPORT, have strategically targeted the U.S. market and generated tremendous growth there. Kuros Biosciences’ U.S. growth was nearly 72% in 2025, while BONESUPPORT grew almost 36%.
Outside the United States, Bioventus grew its pain and joint business 17% and said international markets represent a great opportunity in 2026 and beyond. Anika Therapeutics’ CINGAL surpassed 1 million injections across more than 40 international markets as it gains clinical adoption.
Exhibit 2: Orthobiologics Sales by Region ($million)
| Region | 2025 | 2024 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $4,099.3 | $3,960.2 | $139.1 | 3.5% |
| OUS | $1,765.2 | $1,721.6 | $43.6 | 2.5% |
| EMEA | $967.6 | $943.2 | $24.5 | 2.6% |
| APAC | $639.2 | $625.0 | $14.2 | 2.3% |
| ROW | $158.3 | $153.4 | $4.9 | 3.2% |
| Total | $5,864.5 | $5,681.8 | $182.7 | 3.2% |
Exhibit 3: Orthobiologics Market Share by Region ($million)
Top Companies
Orthobiologics is a large and diverse market leading to a somewhat fragmented landscape. A relatively smooth gradient of revenue spans across the tiers, meaning no company has a dominant market share.
By our estimates, more than 20 companies have at least $50 million in annual revenue, and no company has more than 9.6% market share.
As we’ll show below, orthobiologics is a major M&A target, but the transactions tend to be for smaller companies or select assets. Therefore, we expect the competitive landscape to remain fragmented going forward.
Exhibit 4: Top 10 Orthobiologics Players and All Others ($million)
| Company | 2025 | 2024 | $ Chg | % Chg |
|---|---|---|---|---|
| Medtronic | $563.1 | $546.5 | $16.6 | 3% |
| MTF Biologics | $525.0 | $512.0 | $13.0 | 2.5% |
| Bioventus | $408.3 | $387.2 | $21.0 | 5.4% |
| LifeNet Health | $351.0 | $339.0 | $12.0 | 3.5% |
| J&J MedTech | $343.7 | $350.1 | ($6.4) | (1.8%) |
| Stryker | $328.2 | $324.1 | $4.1 | 1.3% |
| Sanofi | $258.8 | $271.0 | ($12.2) | (4.5%) |
| Heraeus | $252.9 | $239.0 | $13.9 | 5.8% |
| AlloSource | $185.0 | $179.4 | $5.6 | 3.1% |
| Arthrex | $158.9 | $153.1 | $5.7 | 3.8% |
| All Others | $2,489.7 | $2,380.3 | $109.3 | 4.4% |
| Total | $5,864.5 | $5,681.8 | $182.7 | 3.2% |
Exhibit 5: Orthobiologics Market Share by Company ($million)
MTF Biologics expanded its collaboration with Kolosis BIO, adding DBX Mix and DBX Putty, and in 2026, Summit Matrix to the list of products Kolosis distributes for the company.
Bioventus signed an agreement with APEX Biologix to be the exclusive distributor of their XCELL PRP system in the United States for orthopedics and sports medicine, with revenue impact expected in 2026.
Further down the segment’s revenue scale, Globus Medical worked to realign its orthobiologics strategy due to changes in the reimbursement landscape.
Likewise, Orthofix contended with softness in biologics sales while restructuring its commercial channel within the segment.
Zimmer Biomet said it failed to budget adequately for its hyaluronic acid (HA) injection business and had to focus elsewhere amid a bevy of M&A integrations.
Seikgaku saw a slight decline in the Japanese HA injection market and a shift to single injection treatments in the United States
Kuros Biosciences continued opening doors in 2025, hitting the milestone of 100,000 surgeries with MagnetOs, a biologic bone graft technology, and continuing its run as one of the best growth stories in orthopedics.
BONESUPPORT drove excellent growth in the U.S. market during 2025 and announced a change in the regulatory process for the company’s market application to FDA for CERAMENT V for the indication of bone infection. The company transferred the application to the De Novo process, allowing for the opportunity to establish a new product category.
Important Developments in the Orthobiologics Market
Strategic Priority for M&A. Biologics made up 11% of orthopedic M&A from 2016 through 2020. Since 2021, however, the segment accounts for 20% of all deals. That 9% jump makes biologics the fastest-growing segment for M&A in recent years.
M&A activity slowed in 2025, biologics or otherwise, but Heraeus acquired bone void filler and bone substitute products, while Keensight Capital and Demetra were also active. Due to the sheer number of companies with small orthobiologic portfolios, we expect further consolidation to take place in the market.
Growth Engine for Differentiated Players. The United States is the largest orthobiologics market and is highly competitive. Companies like Kuros Biosciences and BONESUPPORT have driven industry-leading growth on the strength of their differentiated offerings.
Kuros Biosciences’ U.S. sales exceeded $140 million in 2025, a massive 71.7% jump from its 2024 total. The company recently expanded its indications to foot and ankle as well as core trauma, extending its runway for strong growth.
BONESUPPORT grew almost 36% in the U.S. market, driven largely by the strength of CERAMENT DE.
Anika Therapeutics continues to navigate the FDA regulatory process for Hyalofast and Cingal, both of which could add significant fuel to the company’s U.S. sales.
Evidence Gap Addressed. Orthobiologics products lack long-term clinical data, as well as inconsistent formulation and dosing standards. In response, surgeon associations are establishing registries and expanding educational initiatives to better differentiate products and guide clinical use.
Across the market, companies will need to invest in robust clinical and economic evidence to demonstrate product efficacy and value.
Further Reading
Thanks for visiting! Need more insight into the orthobiologics market? Questions and comments are always welcome. You can reach me by email. Until then, check out this selection of orthobiologics-related posts from recent months.
January 30, 2026
,
James Petricek and Scott Bruder
December 4, 2025
,
James Petricek and Scott Bruder
August 1, 2025
,
James Petricek and Scott Bruder
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
